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Infection by human T-cell leukemia viruses (HTLV-I and HTLV-II) induces syncytium formation in certain cell types in vitro.
Recombinant vaccinia viruses expressing the HTLV-II envelope (Env) gp61-II were used to infect human cells, and syncytium
formation was observed, demonstrating that HTLV-II Env expression was sufficient to mediate syncytium formation in
appropriate cells. This syncytium formation could be blocked by sera from HTLV-II-infected individuals. Infection with these
recombinant vaccinia viruses caused fusion in mouse/human hybrid cells containing only human chromosome 17, whereas
there was no obvious syncytium formation in mouse cells. This fusogenic phenotype of recombinant gp61-II is likely a
property of the specific interaction between HTLV-II envelope protein and the HTLV cellular receptor, encoded by a gene
that was previously indicated to be on human chromosome 17. On this basis, we developed a sensitive syncytium formation
assay, using lacZ gene activation, for detecting the presence of the HTLV receptor(s). We used this fusion assay to test for
HTLV receptor activity on a variety of cells. Our findings indicate that the HTLV receptor is widely distributed among species
and cell types, including, to a limited extent, murine cells. q 1996 Academic Press, Inc.
The human T-cell leukemia virus types I (HTLV-I) and II esis of the virus and can provide valuable information
(HTLV-II) are pathogenic human retroviruses. They have regarding prevention of viral infection. The cellular re-
been associated with adult T-cell leukemia and hairy- ceptor(s) for HTLV-I and HTLV-II, however, remains un-
cell leukemia, as well as neurological disorders (1, 10, known. Previous experiments, including cross-interfer-
11, 17, 18, 19, 21, 26, 27). The mechanisms by which ence, HTLV-mediated syncytium formation, and vesicu-
HTLV-I and HTLV-II induce malignancy are not clearly lar stomatitis virus (VSV) pseudotyping, indicated that
understood; however, both viruses can immortalize T- HTLV-I and -II likely have the same receptor that is
cells in vitro (6, 25). The env gene of HTLV encodes a encoded by chromosome 17 in humans (22, 23). This
glycoprotein precursor, gp61, which is cleaved to the receptor appears on cells from several species, with
gp46 external glycoprotein and the gp21 transmembrane the possible exclusion of some cell types from mice
glycoprotein (TM) present on infected cells and mature (23). HTLV induces syncytium formation (cell-to-cell fu-
virions (24). As with other enveloped viruses, HTLV likely sion) upon infection of human cells. The syncytium
initiates infection by binding through its envelope glyco- formation in other retroviral infections has been attrib-
protein to a cell surface receptor and subsequent mem- uted to an interaction of viral envelope on the surface
brane fusion, allowing entry of the virus into cells. The of infected cells and viral receptors on the surface of
requirement for cell-to-cell contact for efficient infection neighboring cells. It is therefore likely that HTLV Env-
is a unique property of HTLV and may also be attributed induced syncytium formation is also a result of a simi-
to Env proteins or their interactions with the cellular re- lar interaction of its envelope with viral receptors. In
ceptor(s). this study, we investigated syncytium formation in-
Identification of the HTLV receptor is important in duced by recombinant HTLV-II envelope protein and
understanding the replication, tropism, and pathogen- used it as a biological assay for the presence of the
HTLV receptor on a variety of cell types.
Two recombinant vaccinia viruses, vGP61-II and1 Present address: Myles H. Thaler Center for AIDS and Human
Retrovirus Research, Department of Microbiology, HSC Box 441, Uni- vDK11, expressing full-length HTLV-II Env glycopro-
versity of Virginia, Charlottesville, VA 22908. tein gp61 (gp61-II) (Fig. 1), were generated by recombi-2 Drs. Li and Camerini contributed equally to this study.
nation via either a pSCII vector (4) or a pTM3 vector3 To whom correspondence and reprint requests should be ad-
dressed. (15), in which gp61-II was cloned downstream of the
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human HeLa and BJAB cells. Fusion was observed in
HeLa cells after infection by vDK11 (Fig. 2-I-C) but not
by vDK7, a recombinant vaccinia virus expressing the
lacZ gene (Fig. 2-I-B), or vDK12 (Fig. 2-I-E), a recombi-
nant vaccinia virus expressing only the HTLV-II exter-
nal glycoprotein gp46-II (14). Failure of the external
protein to induce syncytium formation suggests that
the entire HTLV envelope protein, both the external
and transmembrane portions, is required for induction
of cell fusion. This observation was consistent with the
observations that the fusogenic domain is located in
the TM portion of Env (Poon, unpublished observation),
similar to other retroviral Envs (2, 8, 13). vDK11-induced
fusion can be blocked by serum from HTLV-II-infected
individuals (Fig. 2-I-D). Syncytium induction of BJAB
cells by vDK11 infection was also observed (not
shown) and was identical to the syncytium induced
FIG. 1. Expression of recombinant gp61-II glycoprotein by vaccinia when BJAB cells were infected with HTLV-II. Infection
expression vectors. The HTLV-II gp61-encoding DNA sequence from by vGP61-II caused fusion similar to that seen in vDK11
plasmid pH6neo, which encodes a full-length HTLV-II genome (5), was infection. These observations confirmed that expres-
cloned into appropriate vaccinia vectors (see text) for recombination
sion of full-length HTLV-II Env protein alone is suffi-into the vaccinia virus genome, as previously described (14). CV1 cells
cient for the syncytium formation seen during HTLV-IIwere infected with these HTLV-II glycoproteins expressing recombinant
vaccinia viruses. The cells were harvested 48 hr postinfection by treat- infection.
ment with phosphate-buffered saline (PBS)–EDTA (1 mM) and lysed Previous studies utilizing VSV (HTLV-I) pseudotypes
with cell lysis buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 1.5 mM MgCl2 , indicated that the gene encoding the HTLV receptor
and 1% NP-40) to separate the soluble fraction from the pellet by centrif-
maps to chromosome 17 in humans and that severalugation. The soluble fractions were separated on a 10% SDS–PAGE,
murine cells have little HTLV receptor activity (23). Wefollowed by Western blot analysis (AP Systems, Promega, Madison,
WI). The blot was probed with either sera from HTLV-II-infected individ- tested HTLV-II Env-mediated syncytium formation in
uals or SB1 antibody, a previously described anti-HTLV-II envelope murine cells (Fig. 2-II). Infection with vDK11 did not
antibody (14). vTF7-3-infected cells served as a negative control as induce obvious fusion in a murine fibroblast cell line,
indicated. vTF7-3 is a recombinant vaccinia virus that expresses bacte-
A9, but does in MCH313.4 cells, an A9-derived mouse/riophage T7 RNA polymerase (9). vTF7-3/vGP61-II-co-infected cells and
human hybrid that contains only human chromosomevDK11-infected cells are also indicated in this figure. vTF7-3 co-infec-
tion is required for gp61-II expression by vGP61-II. 17 (3), with syncytia induced at levels similar to what
was seen with HeLa cells. This result indicates that
the HTLV-II receptor gene is on human chromosome
17, consistent with previous observations. The require-bacteriophage T7 promoter, respectively. CV-1 cells,
a monkey kidney cell line, were infected with these ment for the HTLV receptor on human chromosome 17
in this gp61-II-mediated fusion of mouse cells sug-two recombinant viruses, and Western blot assays us-
ing HTLV-II-positive human sera or SB1 antibody, gests that this specific fusion can be used as an indica-
tion for the presence of the cellular receptor for HTLV.which specifically recognizes the HTLV-II external gly-
coprotein gp46-II (14), confirmed the expression of re- Nussbaum et al. (16) recently described a sensitive
syncytium formation assay to study fusogenic proper-combinant HTLV-II envelope protein (Fig. 1). The re-
combinant glycoprotein showed an apparent molecu- ties of HIV envelope proteins using cell fusion-medi-
ated reporter gene activation. In this assay, two celllar weight of 61 kilodaltons and did not react with sera
from uninfected individuals (not shown). The back- populations were used, one expressing the T7 RNA
polymerase and the other containing a reporter geneground bands in the human serum panel in Fig. 1 were
attributed to human anti-vaccinia antibodies (data not linked to the T7 promoter. When cell fusion occurred
between the two populations, the reporter gene wasshown). vTF7-3, a recombinant vaccinia virus express-
ing T7 RNA polymerase (9), was needed for co-infec- activated and the degree of the activation could be
used as a quantitative measure of syncytium formation.tion with vGP61-II to express gp61-II.
HTLV-II infection of susceptible human cells such as We developed a similar fusion assay utilizing HTLV-II
envelope-mediated syncytium formation. In this assay,BJAB cells (a B-cell line) causes syncytium formation,
presumably due to the interaction between viral Env cells were also divided into two populations; popula-
tion 1 was co-infected with vGP61-II and vTF7-3, andand cell surface receptors for the virus. We tested the
induction of syncytium formation by vDK11 infection of population 2 was infected with wild-type vaccinia virus,
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FIG. 2.-I Fusion induction in HeLa cells by vGP61-II infection. Confluent HeLa cells in a 24-well plate were infected with HTLV-II glycoprotein
expressing recombinant vaccinia viruses at an m.o.i. of 1. Ten hours postinfection, the cultures were examined microscopically. (A) Uninfected
cells; (B) cells infected with vDK7, a recombinant vaccinia virus expressing b-galactosidase as a negative control; (C) cells infected with vDK11;
(D) cells infected with vDK11, and anti-HTLV-II patient serum was added at a 1:50 dilution; and (E) cells infected with vDK12. vDK12 is a recombinant
vaccinia virus that expresses the HTLV-II external envelope protein gp46-II (14).
WR, and transfected with either pTM3-lacZ or pEM- from mammals, birds, etc. In particular, rat kidney cell
line NRK and all the mouse cells tested are also posi-ClacZbgAn plasmid, in which the Escherichia coli lacZ
gene was linked to the T7 promoter. The two cell popu- tive for receptor activity, albeit at lower levels (23). The
lower level of receptor activity was HTLV-II envelope-lations were mixed and syncytium formation visualized
by in situ staining for b-galactosidase activity. Cells specific, since there was no fusion activity when there
was no expression of the HTLV-II envelope protein andexpressing the HTLV-II envelope protein (population 1)
would fuse with cells expressing the HTLV receptor when anti-HTLV-II serum was added (data not shown).
The experiment was also performed to assess sensi-(population 2) and show blue syncytia in the mixed
culture. By scoring the number and examining the sizes tivity and the semiquantitative nature of this fusion
assay in detecting receptor-positive cells. Two cellof the syncytia, receptor activity on the cells could be
semiquantitatively estimated. lines, HeLa and MPK, a minipig kidney fibroblast cell
line, were used. vGP61-II induces massive syncytiumPrevious studies with cells from different species,
including human, hamster, rat, and mouse, demon- formation in HeLa cells, presumably due to the pres-
ence of high levels of receptor activity on the cells (seestrated HTLV receptor activity in these species, with
the possible exception of rat NRK and some mouse above), while causing only minor fusion in MPK cells,
due to lower levels of receptor activity. As shown incells. We tested a number of cell types from a variety
of species for the HTLV receptor using the vGP61-II- Table 2, when MPK cells of population 1 were mixed
with MPK cells of population 2 that contained an addedmediated fusion assay. All cell lines tested thus far
have shown receptor activity (Table 1), including cells number of HeLa cells, increased giant blue syncytia
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FIG. 2.-II Fusion induction in mouse/human hybrid cells by HTLV-II gp61-II recombinant vaccinia virus infection. A9 mouse fibroblasts were
maintained in Dulbecco’s modified Eagle medium (DMEM) plus 10% calf serum, and MCH313.4 mouse/human hybrid cells were maintained in
DMEM plus 10% calf serum and 800 mg/ml of G418. (A) Uninfected A9 cells; (B) A9 cells infected with vDK11; (C) uninfected MCH313.4 cells; and
(D) MCH313.4 cells infected with vDK11.
were observed, presumably due to increased levels of infection, such as OHH1K, a deer kidney cell line (Ta-
ble 1). Finally, the sensitivity of lacZ gene expressionviral receptors in population 2 resulting from addition
of HeLa cells. Therefore, this fusion assay can detect and the high levels of expression of biologically func-
tional recombinant Env were important in detecting lowas little as 0.1% or less of receptor-positive cells, and
it can semiquantitatively estimate the percentage of levels of cell fusion.
Our results using this sensitive fusion assay confirmedreceptor-positive cells if an appropriate control is pro-
vided. the ubiquitous distribution of the HTLV receptor among
species and cell types, suggesting that the receptor mol-There are several advantages in using this fusion
assay system that combines vaccinia virus infection ecule may be a common biochemical structure that is
highly conserved in different species. Several cell linesand reporter gene activation. First, lacZ gene expres-
sion was not only sensitive, but could also be devel- of murine origin and rat NRK cells were previously shown
to be negative by direct HTLV-mediated fusion. Whenoped as a quantitative assay (16) for study of HTLV
Env-mediated cell fusion. Second, the broad host tested with this fusion assay using vaccinia infection and
lacZ gene expression, these cells were clearly positiverange of vaccinia virus made it possible for us to
screen many cells types for HTLV receptor activity (Ta- for syncytium formation, with some mouse cells at a
lower level. The low level of activity may be due to eitherble 1). There were, however, some cell lines resistant
to vaccinia virus infection, such as MDBK, a bovine a low number of receptor molecules or an interaction of
low affinity. Among the cells tested thus far, C127/LT,kidney cell line, or A6 (26C), a toad kidney cell line,
and some in which the severe cytopathic effects were a polyoma/SV40 hybrid transformed murine mammary
tumor cell line, showed the least amount of syncytiumtoo quickly induced to form syncytia by vaccinia viral
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TABLE 1
HTLV Receptor Activity on Various Cell Lines
Syncytium
Microscopic formation
observation of assay with
Species Cell line syncytium formation the lacZ gene
Human BJAB (B-cell) / ND
HeLa (fibroblast) / ///
Pig PK13 (kidney fibroblast) ? ?
PK15 (kidney fibroblast) / 0
MPK (minipig kidney fibroblast) / /
LLC-PK1 (minipig kidney fibroblast) / /
ESK4 (minipig kidney fibroblast) / /
Cow MDBK (kidney fibroblast) ? ?
LB9K (kidney fibroblast) / ND
BL10K (kidney fibroblast) / ND
FB2 (kidney fibroblast) ? ?
Mouse NIH 3T3 (fibroblast) { //
3T6 (fibroblast) / //
C127/LT (mammary tumor fibroblast) 0 /
A9 (mammary tumor fibroblast) { ND
Mouse/human MCH313 (N/A) / ND
Quail QT6 (fibroblast) / //
QT6-1 (fibroblast) / ND
Chicken 155 (embryonic fibroblast) / //
SL-29 (embryonic fibroblast) / //
Rat Rat-1 (embryonic fibroblast) / //
NRK (kidney fibroblast) / //
Deer OHH1K (kidney fibroblast) ? ?
Toad A6 (26C) (kidney fibroblast) ? ?
Potoroo PTK2 (kidney fibroblast) / ND
Monkey CV1a (kidney fibroblast) / ND
CV1b (kidney fibroblast) 0 ND
Cat CRFK (kidney fibroblast) / ND
Oppossum MDOK (kidney fibroblast) { //
Dog MDCK (kidney fibroblast) / //
DK (kidney fibroblast) /// ND
Note. Syncytium formations induced by recombinant vaccinia viruses expressing gp61-II in various cell types were assayed, and the results are
summarized in the table. The microscopic syncytium formation assay is described in Figs. 1 and 2. The syncytium formation assay with lacZ gene
activation was performed as follows. The cells to be tested were seeded into 6-well plates (5 1 105 cells/well) on Day 1. On Day 2, one of the
wells was co-infected with vTF7-3 and vGP61-II (m.o.i.  1) (population 1), and another (population 2) was infected with the wild-type vaccinia virus
strain WR (m.o.i. 1) transfected with 2 mg plasmid DNA from either pEMClacZbgAn (7) or pTM3-lacZ (the lacZ gene is cloned into the NcoI and
BamHI sites of the pTM3 vector) 2 hr postinfection. pTM3-lacZ and pEMClacZbgAn worked equally well in this assay. Sixteen hours postinfection,
the cells in both wells were harvested by treatment with PBS–EDTA and washed once with media. Both groups of cells were counted, and 105
cells from each of the two sources were mixed and replated in 1 well of a 24-well plate in the presence of actinomycin D (1 mg/ml), which was
used to block vaccina virus spread after cell mixing. The mixed cells were incubated for 7 hr, and the cultures fixed and stained in situ for 1 hr at
377 with solution containing 4 mM potassium ferrocyanide, 2 mM MgCl2, and 0.5 mg X-Gal per milliliter. The reaction was stopped by removing
the staining solution and washing with PBS twice (12). The giant blue syncytia were counted microscopically. Two additional pairs of the cell
populations from the 6-well plate were used as controls. For a positive control, the well to be transfected (population 2) had 1000 HeLa cells in
addition to the cells to be tested, and for a negative control, vGP61-II virus was omitted in population 1 for background control. For microscopic
observation of syncytium formation, ‘‘/’’ indicates positive for fusion, ‘‘0’’ indicates negative, ‘‘{’’ indicates borderline, and ‘‘ND’’ indicates ‘‘not
determined.’’ ‘‘?’’ indicates that the assay was inconclusive due to noninfectibility by vaccinia virus, low or no transfectability, or severe cytolytic
effects induced by vaccinia virus before the syncytium could be visualized. For syncytium formation assays with the lacZ gene, ‘‘///’’ indicates
300 giant syncytia counted in the well, ‘‘//’’ indicates between 50 and 300 syncytia, ‘‘/’’ indicates between 10 and 50 syncytia, and ‘‘0’’ indicates
10 syncytia. Increased numbers of syncytia usually correlated to increased sizes of the syncytia.
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